Assessment of Current and Future Opportunities and Threats in the Insomnia Market in the US, EU and Japanese Pharmaceutical Markets.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c33616) has announced the addition of Pipeline and Commercial Perspectives: Insomnia insomnia, abnormal wakefulness or inability to sleep. The condition may result from illness or physical discomfort, or it may be caused by stimulants such as coffee or drugs. However, frequently some psychological factor, such as worry or tension, is the cause. to their offering Until recently, the insomnia market has been dominated by Ambien, Sonata sonata (sənä`tə), in music, type of instrumental composition that arose in Italy in the 17th cent. At first the term merely distinguished an instrumental piece from a piece with voice, which was called a cantata. , and Imovane, and the older hypnotics such as benzodiazepines Benzodiazepines Definition Benzodiazepines are medicines that help relieve nervousness, tension, and other symptoms by slowing the central nervous system. Purpose Benzodiazepines are a type of antianxiety drugs. . However, the global insomnia market is set to grow from $3.7 billion in 2005 to $5.5 billion by 2014 (CAGR CAGR See: Compound Annual Growth Rate , 5.6% 200514), driven primarily by the launch and up-take of Lunesta, Rozerem and Ambien CR Ambien CR (zolpidem tartrate extended release) is different from Ambien (zolpidem tartrate) in that the medication is formulated in a 2 layer tablet. The first layer of the Ambien CR tablet dissolves quickly to help people fall asleep, while the 2nd layer dissolves slowly over the as well as pipeline drugs from 2006 onwards on·ward adj. Moving or tending forward. adv. also on·wards In a direction or toward a position that is ahead in space or time; forward. Adv. 1. . Scope of this title: - Overview of current market including profiles of key brands and key events impacting each brand during 2004-2005 - Assessment of current and future opportunities and threats in the insomnia market in the US, EU and Japanese pharmaceutical markets - Examination of the hypnotics pipeline with in-depth clinical and commercial profiles of late-stage candidates, with We and KOL KOL Kings of Leon (UK band) KoL Kingdom of Loathing (online game) KOL Key Opinion Leaders KOL Key Opinion Leader KOL Kiss on Lips KOL Key Objects Library KOL Knights of Labor KOL Key-Oriented List opinions - In-depth discussion of assumptions and events used in forecast analysis Highlights of this title: Ambien with US revenues of $2 billion in 2004 faces competition from recently launched hypnotics, and will experience genericization from 2006. Sanofi-Aventis launched Ambien CR in the US during October 2005, although this report forecasts that the Ambien franchise will decline from 2006 onwards to approximately half the value it is today by 2014. By 2014, prospective players can expect to face stiff competition from numerous generics, worth nearly $800m, as well as a number of non-GABA A, non-scheduled hypnotics with revenues topping $700m. In such a crowded market, innovation is key and product differentiation Product Differentiation A source of competitive advantage that depends on producing some item that is regarded to have unique and valuable characteristics. , demonstration of cost-effectiveness and niche strategies are essential. The transient insomnia market is severely under served, and presents an ideal niche for manufacturers. If manufacturers can increase the proportion of individuals using prescription hypnotics at least a few nights a month, to the level of those who use them at least a few times a week, usage of prescription hypnotics could increase by 50%. Reasons to order your copy: - Understand the challenge faced by established hypnotics by the emergence of generic competition - Develop strategies to grow the value of niche patient groups, such as the transient insomnia market - Benchmark recently launched and pipeline hypnotics against Ambien and assess their future market potential Chapters Include:- Chapter 1 Executive summary Chapter 2 Patient potential Chapter 3 Market overview Chapter 4 Country market assessment Chapter 5 R&D approach Chapter 6 Recently launched hypnotic hypnotic /hyp·not·ic/ (hip-not´ik) 1. inducing sleep. 2. an agent that induces sleep. 3. pertaining to or of the nature of hypnosis or hypnotism. analysis & forecasts Chapter 7 Late-stage pipeline hypnotic analysis & forecasts Chapter 8 Forecast analysis Chapter 9 Commercial impact and lifecycle management: case studies For more information visit http://www.researchandmarkets.com/reports/c33616 Datamonitor |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion